Atara Biotherapeutics, Inc. (ATRA)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | — | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-16) · 99.1 | 8-K (2026-01-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-11) · 99.1 | 8-K (2025-07-14) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-15) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-07) · 99.1 | 8-K (2025-01-16) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-12) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-09) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-28) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-01) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-08) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Condensed Consolidated Statements of Operations and Comprehensive Income (loss) (unaudited) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Changes In Stockholders' Equity (unaudited) | — |
|
| Consolidated Statements of Stockholders' Equity (deficit) | — |
|
| Condensed Consolidated Statements of Changes In Stockholders' Equity (P) (unaudited) | — |
|
| Consolidated Statements of Stockholders' Equity (P) | — |
|
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Description of Business | ||
| Financial Instruments | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| Liability Related To The Sale of Future Revenues | — |
|
| Liability Related To The Sale of Future Royalties | — |
|
| Net Income (loss) Per Common Share | — |
|
| Net Loss Per Common Share | ||
| Out-license Agreements | ||
| Pay Vs Performance Disclosure | ||
| Restructuring | ||
| Sale of Atom Facility | — |
|
| Stockholders' Equity | ||
| Stockholders' Equity (deficit) | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Supplemental Balance Sheet Information | ||